Concord Biotech has reported results for third quarter ended December 31, 2024 (Q3FY25).
The company has reported marginal decline of 0.62% in its net profit at Rs 74.09 crore for Q3FY25 as compared to Rs 74.55 crore for the same quarter in the previous year. However, total income of the company increased marginally by 4% at Rs 258.95 crore for Q3FY25 as compared to Rs 248.98 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported marginal decline of 2.13% in its net profit at Rs 75.92 crore for the quarter ended December 31, 2024 as compared to Rs 77.57 crore for the same quarter in the previous year. However, total income of the company increased marginally by 4% at Rs 258.95 crore for Q3FY25 as compared to Rs 248.98 crore for the corresponding quarter previous year.
